Antibody Screening News and Research

RSS

Sino Biological launches precisely characterized full-length p-Tau217 protein to advance next-generation Alzheimer’s Biomarker assay development

Sino Biological Inc. is pleased to announce the launch of its Recombinant Human p-Tau217 Protein (Cat. No. T08-50SN), a full-length, tag-free Tau reagent developed to support Alzheimer’s disease biomarker assay development, antibody evaluation, and Tau biology research.

From Sino Biological Inc. 4 Aug 2026

Sino Biological launches XPressMAX™ Cell-Free Protein Synthesis Kit, accelerating AI-powered high-throughput antibody drug discovery

Sino Biological, Inc., a global leader in recombinant technology, is proud to announce the launch of its innovative XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02) , a cutting-edge solution designed to supercharge artificial intelligence (AI)-driven high-throughput screening pipelines for antibody drug discovery.

From Sino Biological Inc. 20 May 2026

Nuclera launches antibody triage service to advance AI-driven antibody discovery

Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its antibody screening service to streamline the transition from antibody hit generation to lead selection.

From Nuclera 11 May 2026

New autoimmune target identified in pediatric idiopathic nephrotic syndrome

Idiopathic nephrotic syndrome (INS) is a serious kidney disease in children with no clear cause. In a recent study, researchers have identified a novel autoantibody targeting vinculin—a protein crucial for kidney cell structure—as a significant factor in INS.

14 Jul 2025

Scaling B-cell cloning workflows for antibody development

Explore the latest tools that boost speed and accuracy in B-cell cloning processes.

From Cellenion 24 Jun 2025

Autoantibodies against vinculin linked to childhood kidney disease

19 Jun 2025

Study reveals 15 hidden genetic risk factors for celiac disease

This comprehensive GWAS reveals 15 new genetic variants linked to celiac disease, offering insights for earlier detection and tailored treatment strategies.

9 Jun 2025

AI-powered treatment allocation improves public health outcomes

A new study sheds light on a promising approach using machine learning to more effectively allocate medical treatments during a pandemic or any time there's a shortage of therapeutics.

14 Sep 2024

Gyros Protein Technologies introduces Gyrolab Generic Anti-AAV Kit to support gene therapy development

Ready-to-use kit enables detection of binding antibodies against AAV vectors without the need for serotype-specific assays.

From Gyros Protein Technologies AB 17 Jun 2024

CDC releases new syphilis testing guidelines to combat rising cases

The CDC's new guidelines in the Morbidity and Mortality Weekly Report outline comprehensive testing protocols for syphilis diagnosis, emphasizing the combined use of nontreponemal and treponemal tests to improve detection and management of the disease in the U.S.

11 Feb 2024

Empowering oncology research: Transmembrane proteins and cutting-edge production platforms

In this Interview, Dr. Fang-Yi Chu talks to NewsMed about the role of transmembrane proteins in targeting oncology research.

From Sino Biological Inc. 23 Nov 2023

Universal screening: A game-changer in early detection and management of type 1 diabetes

Dr. Emily K. Sims discusses the crucial role of universal type 1 diabetes (T1D) screening in early detection, especially in individuals without a family history, at the EASD Annual Meeting. This proactive approach, aligned with disease-modifying therapies, aims to prevent severe diabetic ketoacidosis episodes, marking a stride towards better management of T1D.

3 Oct 2023

Artificial intelligence and polyclonal antibody sequencing redefine the future of antibody discovery

In this interview, News-Medical had the opportunity to speak with Dr. Xiaobing Han, Principal Scientist for Antibody Discovery at Rapid Novor.

From Rapid Novor Inc 23 Aug 2023

PhenomeX Launches Beacon Select™ Optofluidic System with Opto® B Discovery Workflows

Affordable two-chip Beacon Select system to broaden customer access to innovative high throughput, function-first antibody discovery capabilities.

From Bruker Cellular Analysis 16 May 2023

Seroprevalence measurements reveal a higher incidence of asymptomatic SARS-CoV-2 infections among residents of three federal German states

Researchers measured the seroprevalence against SARS-CoV-2 in blood donors from the states of Hesse, Lower Saxony, and North Rhine-Westphalia in Germany to determine the incidence of undetected asymptomatic SARS-CoV-2 infections.

20 Dec 2022

Creoptix launches new WAVEcontrol software to deliver automated, flexible and intuitive label-free interaction analysis for biologics drug-discovery

Creoptix® (a Malvern Panalytical brand) is announcing the addition of two new wizards to their WAVEcontrol software to simplify and streamline workflows. By combining the high sensitivity, throughput, and no-clog microfluidics of the WAVEsystem, with a faster, more flexible, automated approach to screening and characterization, Creoptix is accelerating biologics drug discovery and diagnostics development.

From Malvern Panalytical 7 Sep 2022

LJI acquires Carterra LSA instrument to enhance antibody screening and characterization efforts

Carterra, Inc., the world leader in innovative technologies enabling high-throughput biology, and La Jolla Institute for Immunology, a globally recognized non-profit research organization dedicated to understanding the power of the immune system to promote human health, announced today that LJI has acquired a Carterra LSA instrument to enhance its antibody screening and characterization work.

2 Aug 2022

The potential of tixagevimab–cilgavimab for treating hospitalized COVID-19 patients

Scientists assessed the potential of tixagevimab–cilgavimab for treating hospitalized SARS-CoV-2 patients.

13 Jul 2022

Real-world study shows Paxlovid associated with lower hospitalization rates

In a recent study posted to the medRxiv* pre-print server, researchers investigated the effectiveness of nirmatrelvir plus ritonavir in preventing hospitalizations among individuals aged 50 or older and vaccinated for coronavirus disease 2019 (COVID-19).

20 Jun 2022

Hybrid alphavirus-SARS-CoV-2 pseudovirus system rapidly measures neutralizing antibodies

Do a person's antibodies work to block the COVID-19 virus from infecting one's system? Are these antibodies also capable of blocking emerging variants such as the omicrons?

21 Apr 2022